Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (131-140 of 635) with videos related to

Pageof 64
Sort By:
Thrombosis and Haemostasis|February 15, 2018
Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO StudyRobert F Storey, Diego Ardissino, Luigi Vignali, et al.
Medrxiv : the Preprint Server for Health Sciences|July 14, 2025
<i>CARS</i> 2 Hypermethylation Is a Risk Factor for Stage B Heart Failure and Hospitalizations in the Project Baseline Health StudyJessica A Regan, Jordan Franklin, Kalyani Kottilil, et al.
Diabetes, Obesity & Metabolism|October 26, 2023
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trialAbhinav Sharma, Pedro Marques, Brendon L Neuen, et al.
Circulation. Genomic and Precision Medicine|October 6, 2025
<i>CARS2</i> Hypermethylation Is a Risk Factor for Heart Failure: A Project Baseline Health SubstudyJessica A Regan, Jordan Franklin, Kalyani Kottilil, et al.
ESC Heart Failure|November 21, 2019
Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failureAbhinav Sharma, Jingjing Wu, Justin A Ezekowitz, et al.
Diabetologia|August 11, 2019
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS ProgramZien Zhou, Meg Jardine, Vlado Perkovic, et al.
Circulation. Cardiovascular Interventions|August 17, 2019
Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary InterventionChristoph B Olivier, Jun Fan, Mariam Askari, et al.
American Heart Journal|September 25, 2004
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndromeHassan Kassem-Moussa, Kenneth W Mahaffey, Carmelo Graffagnino, et al.
Journal of the American Society of Hypertension : JASH|November 14, 2015
Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunctionTatiana Kuznetsova, Francois Haddad, Judita Knez, et al.
Diabetes Care|January 22, 2024
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE TrialsSheldon W Tobe, Thomas A Mavrakanas, Harpreet S Bajaj, et al.
Pageof 64

Showing results (131-140 of 635) with videos related to

Sort By:
Pageof 64
Thrombosis and Haemostasis|February 15, 2018
Ischaemic Events and Stent Thrombosis following Planned Discontinuation of Study Treatment with Ticagrelor or Clopidogrel in the PLATO StudyRobert F Storey, Diego Ardissino, Luigi Vignali, et al.
Medrxiv : the Preprint Server for Health Sciences|July 14, 2025
<i>CARS</i> 2 Hypermethylation Is a Risk Factor for Stage B Heart Failure and Hospitalizations in the Project Baseline Health StudyJessica A Regan, Jordan Franklin, Kalyani Kottilil, et al.
Diabetes, Obesity & Metabolism|October 26, 2023
Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trialAbhinav Sharma, Pedro Marques, Brendon L Neuen, et al.
Circulation. Genomic and Precision Medicine|October 6, 2025
<i>CARS2</i> Hypermethylation Is a Risk Factor for Heart Failure: A Project Baseline Health SubstudyJessica A Regan, Jordan Franklin, Kalyani Kottilil, et al.
ESC Heart Failure|November 21, 2019
Eligibility of sodium-glucose co-transporter-2 inhibitors among patients with diabetes mellitus admitted for heart failureAbhinav Sharma, Jingjing Wu, Justin A Ezekowitz, et al.
Diabetologia|August 11, 2019
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS ProgramZien Zhou, Meg Jardine, Vlado Perkovic, et al.
Circulation. Cardiovascular Interventions|August 17, 2019
Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary InterventionChristoph B Olivier, Jun Fan, Mariam Askari, et al.
American Heart Journal|September 25, 2004
Incidence and characteristics of stroke during 90-day follow-up in patients stabilized after an acute coronary syndromeHassan Kassem-Moussa, Kenneth W Mahaffey, Carmelo Graffagnino, et al.
Journal of the American Society of Hypertension : JASH|November 14, 2015
Cytokines profile in hypertensive patients with left ventricular remodeling and dysfunctionTatiana Kuznetsova, Francois Haddad, Judita Knez, et al.
Diabetes Care|January 22, 2024
Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE TrialsSheldon W Tobe, Thomas A Mavrakanas, Harpreet S Bajaj, et al.
Pageof 64